Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
53.88
-0.20 (-0.37%)
At close: Oct 10, 2025, 4:00 PM EDT
53.86
-0.02 (-0.04%)
After-hours: Oct 10, 2025, 7:51 PM EDT

Akero Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202018 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Selling, General & Admin
41.1437.9331.0729.8719.1315.24
Upgrade
Research & Development
280.35247.5141.885.2881.7664.92
Upgrade
Total Operating Expenses
321.48285.42172.87115.16100.8980.15
Upgrade
Operating Income
-321.48-285.42-172.87-115.16-100.89-80.15
Upgrade
Interest Income
42.338.0324.213.860.110.95
Upgrade
Interest Expense
-4.77-4.67-3.1-0.74--
Upgrade
Total Non-Operating Income (Expense)
37.5233.3621.113.120.110.95
Upgrade
Pretax Income
-283.96-252.06-151.76-112.03-100.78-79.21
Upgrade
Net Income
-283.96-252.06-151.76-112.03-100.78-79.21
Upgrade
Net Income to Common
-283.96-252.06-151.76-112.03-100.78-79.21
Upgrade
Shares Outstanding (Basic)
756753393531
Upgrade
Shares Outstanding (Diluted)
756753393531
Upgrade
Shares Change (YoY)
25.28%27.71%34.84%11.94%10.69%108.77%
Upgrade
EPS (Basic)
-3.80-3.75-2.89-2.87-2.89-2.52
Upgrade
EPS (Diluted)
-3.80-3.75-2.89-2.87-2.89-2.52
Upgrade
Free Cash Flow
-253.42-230.11-145.37-92.52-79.68-70.95
Upgrade
Free Cash Flow Per Share
-3.37-3.43-2.77-2.37-2.29-2.26
Upgrade
EBITDA
-321.22-285.15-172.61-114.9-100.64-79.94
Upgrade
EBIT
-321.48-285.42-172.87-115.16-100.89-80.15
Upgrade
Updated Aug 8, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q